Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 7 (July)

1. Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.
   Br J Cancer, 101(1): 185-91. [Abstract] [Full-text]
2. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.
   Br J Cancer, 101(1): 19-26. [Abstract] [Full-text]
3. Racial differences in risk of prostate cancer associated with metabolic syndrome.
   Urology, 74(1): 185-90. [Abstract] [Full-text]
4. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
   Urology, 74(1): 177-83. [Abstract] [Full-text]
5. Prevalence of erectile dysfunction in men screened for prostate cancer.
   Urology, 74(1): 89-93. [Abstract] [Full-text]
6. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?
   Urology, 74(1): 167-70. [Abstract] [Full-text]
7. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
   Urology, 74(1): 171-6. [Abstract] [Full-text]
8. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis.
   Carcinogenesis, 30(7): 1125-31. [Abstract] [Full-text]
9. Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.
   Carcinogenesis, 30(7): 1082-8. [Abstract] [Full-text]
10. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.
    Cancer Res, 69(13): 5601-9. [Abstract] [Full-text]
11. Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
    Cancer Res, 69(13): 5568-74. [Abstract] [Full-text]
12. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status.
    Biochem Pharmacol, 78(5): 469-76. [Abstract] [Full-text]
13. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.
    Endocrine, 36(1): 87-97. [Abstract] [Full-text]
14. Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer.
    Med Care Res Rev, 66(4): 409-35. [Abstract] [Full-text]
15. Screening for prostate cancer.
    CA Cancer J Clin, 59(4): 264-73. [Abstract] [Full-text]
16. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
    Med Hypotheses, 73(3): 387-8. [Abstract] [Full-text]
17. Expression of the Bcl-2 protein BAD promotes prostate cancer growth.
    PLoS One, 4(7): e6224. [Abstract] [Full-text]
18. Neuroendocrine differentiation of LNCaP cells suggests: VDAC in the cell membrane is involved in the extrinsic apoptotic pathway.
    Mol Genet Metab, 97(4): 241-3. [Abstract] [Full-text]
19. A comparison of prone three-dimensional conformal radiotherapy with supine intensity-modulated radiotherapy for prostate cancer: which technique is more effective for rectal sparing?
    Br J Radiol, 82(980): 654-61. [Abstract] [Full-text]
20. Characterization of preclinical models of prostate cancer using PET-based molecular imaging.
    Eur J Nucl Med Mol Imaging, 36(8): 1245-55. [Abstract] [Full-text]
21. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells.
    Cancer Genet Cytogenet, 192(2): 60-7. [Abstract] [Full-text]
22. DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness.
    J Urol, 182(2): 756-61. [Abstract] [Full-text]
23. Duplicate presentations on prostate cancer at American Urological Association and European Association of Urology annual meetings.
    J Urol, 182(2): 674-8; discussion 678-9. [Abstract] [Full-text]
24. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    J Urol, 182(2): 517-25; discussion 525-7. [Abstract] [Full-text]
25. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
    J Urol, 182(2): 485-90; discussion 490. [Abstract] [Full-text]
26. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    J Urol, 182(2): 491-6; discussion 496-8. [Abstract] [Full-text]
27. Chemoprevention of prostate cancer.
    J Urol, 182(2): 499-507; discussion 508. [Abstract] [Full-text]
28. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    J Urol, 182(2): 509-15; discussion 515-6. [Abstract] [Full-text]
29. The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese.
    J Surg Oncol, 100(2): 106-10. [Abstract] [Full-text]
30. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
    Nucleic Acids Res, 37(12): 4135-48. [Abstract] [Full-text]
31. Dural metastasis from prostatic adenocarcinoma mimicking chronic subdural hematoma.
    J Clin Neurosci, 16(8): 1084-6. [Abstract] [Full-text]
32. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
    J Pathol, 218(4): 505-13. [Abstract] [Full-text]
33. Oxidative stress in prostate cancer.
    Cancer Lett, 282(2): 125-36. [Abstract] [Full-text]
34. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
    Br J Cancer, 101(2): 263-8. [Abstract] [Full-text]
35. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.
    Bioorg Med Chem, 17(14): 4888-93. [Abstract] [Full-text]
36. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer.
    J Pineal Res, 47(1): 8-14. [Abstract] [Full-text]
37. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
    Am J Clin Pathol, 132(2): 211-20; quiz 307. [Abstract] [Full-text]
38. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.
    Clin Cancer Res, 15(14): 4694-9. [Abstract] [Full-text]
39. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Clin Cancer Res, 15(14): 4706-11. [Abstract] [Full-text]
40. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Cancer Res, 69(14): 5893-900. [Abstract] [Full-text]
41. A brainstem paraneoplastic syndrome associated with prostate cancer.
    J Neurol Neurosurg Psychiatry, 80(8): 934-5. [Abstract] [Full-text]
42. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.
    J Clin Oncol, 27(21): 3547-56. [Abstract] [Full-text]
43. Antibody-specific detection of CAIX in breast and prostate cancers.
    Biochem Biophys Res Commun, 386(3): 488-92. [Abstract] [Full-text]
44. Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score.
    Med Image Anal, 13(4): 609-20. [Abstract] [Full-text]
45. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
    J Clin Oncol, 27(21): 3459-64. [Abstract] [Full-text]
46. Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(5): 1609-16. [Abstract] [Full-text]
47. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.
    Int J Radiat Oncol Biol Phys, 74(5): 1405-18. [Abstract] [Full-text]
48. Effect of translational and rotational errors on complex dose distributions with off-line and on-line position verification.
    Int J Radiat Oncol Biol Phys, 74(5): 1600-8. [Abstract] [Full-text]
49. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
    Int J Radiat Oncol Biol Phys, 74(5): 1441-6. [Abstract] [Full-text]
50. Internal audit of a comprehensive IMRT program for prostate cancer: a model for centers in developing countries?
    Int J Radiat Oncol Biol Phys, 74(5): 1447-54. [Abstract] [Full-text]
51. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy.
    Int J Radiat Oncol Biol Phys, 74(5): 1431-40. [Abstract] [Full-text]
52. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 74(5): 1424-30. [Abstract] [Full-text]
53. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Int J Radiat Oncol Biol Phys, 74(5): 1419-23. [Abstract] [Full-text]
54. Insomnia, depression, and distress among outpatients with prostate cancer.
    Appl Nurs Res, 22(3): 154-8. [Abstract] [Full-text]
55. Risk factors, prevention and early detection of prostate cancer.
    Prim Care, 36(3): 603-21. [Abstract] [Full-text]
56. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Anal Biochem, 392(2): 117-25. [Abstract] [Full-text]
57. Expression, regulation and function of the ISGylation system in prostate cancer.
    Oncogene, 28(28): 2606-20. [Abstract] [Full-text]
58. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    BJU Int, 104(3): 310-4. [Abstract] [Full-text]
59. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
    BJU Int, 104(3): 304-9. [Abstract] [Full-text]
60. Is farm-related job title an adequate surrogate for pesticide exposure in occupational cancer epidemiology?
    Occup Environ Med, 66(8): 497-501. [Abstract] [Full-text]
61. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
    BJU Int, 104(3): 321-5. [Abstract] [Full-text]
62. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy.
    BJU Int, 104(3): 315-20. [Abstract] [Full-text]
63. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.
    Int J Cancer, 125(6): 1372-9. [Abstract] [Full-text]
64. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis.
    Int J Cancer, 125(6): 1414-23. [Abstract] [Full-text]
65. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
    Int J Cancer, 125(5): 1143-6. [Abstract] [Full-text]
66. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.
    Cancer Lett, 283(1): 29-35. [Abstract] [Full-text]
67. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
    Proc Natl Acad Sci U S A, 106(29): 12178-83. [Abstract] [Full-text]
68. Prostate cancer regulatory networks.
    J Cell Biochem, 107(5): 845-52. [Abstract] [Full-text]
69. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.
    J Cell Biochem, 107(5): 992-1001. [Abstract] [Full-text]
70. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
    Prostate, 69(12): 1334-42. [Abstract] [Full-text]
71. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells.
    Prostate, 69(12): 1343-52. [Abstract] [Full-text]
72. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
    Prostate, 69(12): 1270-80. [Abstract] [Full-text]
73. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.
    Prostate, 69(12): 1325-33. [Abstract] [Full-text]
74. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
    Prostate, 69(12): 1303-11. [Abstract] [Full-text]
75. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Prostate, 69(12): 1292-302. [Abstract] [Full-text]
76. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
    Prostate, 69(12): 1257-69. [Abstract] [Full-text]
77. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.
    Prostate, 69(12): 1281-91. [Abstract] [Full-text]
78. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
    Prostate, 69(12): 1312-24. [Abstract] [Full-text]
79. The Del1 deposition domain can immobilize 3alpha-hydroxysteroid dehydrogenase in the extracellular matrix without interfering with enzymatic activity.
    Bioprocess Biosyst Eng, 32(5): 569-73. [Abstract] [Full-text]
80. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
    Cell, 138(2): 245-56. [Abstract] [Full-text]
81. NF-kappaB regulates androgen receptor expression and prostate cancer growth.
    Am J Pathol, 175(2): 489-99. [Abstract] [Full-text]
82. Suppressive roles of calreticulin in prostate cancer growth and metastasis.
    Am J Pathol, 175(2): 882-90. [Abstract] [Full-text]
83. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Cancer, 115(15): 3437-45. [Abstract] [Full-text]
84. Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging.
    Exp Biol Med (Maywood), 234(8): 860-79. [Abstract] [Full-text]
85. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
    Cancer, 115(15): 3446-56. [Abstract] [Full-text]
86. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Cancer, 115(15): 3468-74. [Abstract] [Full-text]
87. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
    Comput Methods Programs Biomed, 96(1): 33-41. [Abstract] [Full-text]
88. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach.
    Cancer Invest, 27(7): 794-801. [Abstract] [Full-text]
89. Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians.
    PLoS One, 4(7): e6370. [Abstract] [Full-text]
90. Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population.
    BMC Urol, 9: 7. [Abstract] [Full-text]
91. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study.
    Br J Cancer, 101(3): 390-4. [Abstract] [Full-text]
92. Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer, 101(3): 522-5. [Abstract] [Full-text]
93. An improved method for constructing tissue microarrays from prostate needle biopsy specimens.
    J Clin Pathol, 62(8): 694-8. [Abstract] [Full-text]
94. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
    J Magn Reson Imaging, 30(2): 327-34. [Abstract] [Full-text]
95. Combined T2-weighted and diffusion-weighted MRI for diagnosis of urinary bladder invasion in patients with prostate carcinoma.
    J Magn Reson Imaging, 30(2): 351-6. [Abstract] [Full-text]
96. Characterization of response to radiation mediated gene therapy by means of multimodality imaging.
    Magn Reson Med, 62(2): 348-56. [Abstract] [Full-text]
97. Passing through the wall: on outings, exodus, angels, and the ark.
    J Relig Health, 48(3): 381-90. [Abstract] [Full-text]
98. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
    Oncogene, 28(30): 2756-65. [Abstract] [Full-text]
99. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
    Urol Int, 83(1): 122-4. [Abstract] [Full-text]
100. Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms.
     Urol Int, 83(1): 60-5. [Abstract] [Full-text]
101. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men.
     Carcinogenesis, 30(8): 1372-9. [Abstract] [Full-text]
102. Novel single nucleotide polymorphism associations with colorectal cancer on chromosome 8q24 in African and European Americans.
     Carcinogenesis, 30(8): 1353-7. [Abstract] [Full-text]
103. Health-related quality of life using SF-8 and EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy.
     Jpn J Clin Oncol, 39(8): 502-8. [Abstract] [Full-text]
104. Cytokine genetic polymorphisms and prostate cancer aggressiveness.
     Carcinogenesis, 30(8): 1358-62. [Abstract] [Full-text]
105. Putative health risks associated with vasectomy.
     Urol Clin North Am, 36(3): 337-45. [Abstract] [Full-text]
106. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.
     Cancer Res, 69(15): 6042-8. [Abstract] [Full-text]
107. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
     Cancer Res, 69(15): 6256-64. [Abstract] [Full-text]
108. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
     Cancer Res, 69(15): 6027-32. [Abstract] [Full-text]
109. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells.
     Biochem Biophys Res Commun, 387(1): 196-201. [Abstract] [Full-text]
110. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
     Nucl Med Commun, 30(9): 693-9. [Abstract] [Full-text]
111. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
     J Clin Oncol, 27(22): 3577-83. [Abstract] [Full-text]
112. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
     J Clin Oncol, 27(22): 3591-7. [Abstract] [Full-text]
113. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
     Mod Pathol, 22(8): 1083-93. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.